ArticleCureus2025
Real-World Evaluation of the Efficacy and Tolerability of a Fixed-Dose Combination of Amlodipine and Indapamide in Patients Over 55 Years.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIsolated systolic hypertension (ISH) is a major cardiovascular risk factor in older adults, yet blood pressure (BP) control remains suboptimal. This study assessed the real-world effectiveness and tolerability of a FDC of indapamide and amlodipine in Bangladeshi patients aged 55 years and older.
methodsThe COMBINE (COMBination of Indapamide and amlodipiNE) study was an open-label, multicenter, prospective observational study conducted across 10 tertiary centers in Bangladesh from June to October 2022. A total of 185 patients with ISH, defined as systolic BP (SBP) between 140 and 179 mmHg (millimeters of mercury), received indapamide 1.5 mg and amlodipine 5 mg once daily. Primary endpoints included the mean SBP change and the proportion achieving SBP targets (<140 mmHg, <130 mmHg). BP, adverse events, and patient-reported well-being were assessed using the visual analogue scale (VAS).
resultsThe mean SBP decreased by 20.9, 24.7, and 29.3 mmHg (p < 0.001); mean diastolic BP (DBP) declined by 8.1, 10.4, and 12.9 mmHg (p < 0.001) at two, four, and 12 weeks, respectively. At 12 weeks, most patients (164, 88.6%) achieved SBP <140 mmHg, and over half (115, 62.2%) of patients reached SBP <130 mmHg. Pulse pressure also improved significantly. The treatment was well tolerated, with mild adverse events including leg edema in three (1.6%) and hypokalemia in four (2.2%). VAS scores improved significantly, reflecting enhanced patient-perceived health status.
conclusionsIn his real-world study, therapy was associated with substantial BP reductions, target SBP achievement, good tolerability, and improved patient-reported well-being in older adults with ISH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.